

## **Radiopharm Theranostics receives US\$2.0 M payment from Lantheus Holdings, Inc**

- Lantheus, a leading global radiopharmaceutical company, has paid US\$2.0 million under the preclinical assets transfer and development agreement announced on 20 June 2024.
- Payment is separate to A\$7.5 million (US\$4.99 million ) investment by Lantheus in RAD, which is subject to shareholder approval at an EGM on 14 August 2024

Sydney, Australia – 5 August 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has received a payment of A\$3.0 million (US\$2.0 million) from Nasdaq listed Lantheus Holdings Inc (Nasdaq:LNTH).

This payment is in accordance with the preclinical assets transfer and development agreement announced on 20 June 2024.

This payment forms part of a total investment package in RAD previously announced to the market on 20 June 2024 which includes:

- An initial investment in RAD of A\$7.5 million (US\$4.99 million) at 5 cents a share, a premium of 47% over the share price at that time;
- Potential further investment of up to A\$7.5 million (US\$5.0 million) via options with a six month term exercisable at 5 cents per share;
- the A\$3.0 million (US\$2.0 million ) preclinical assets transfer and development agreement referred to in this announcement.

RAD’s CEO & MD, Riccardo Canevari said “I am delighted with the confidence demonstrated by Lantheus in settling the transfer and development agreement and making this payment ahead of the shareholder meeting later this month. We are well advanced in our strategic planning with Lantheus and the collaboration between our two companies augers well for the future.”

### **About Radiopharm Theranostics**

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. Learn more at [Radiopharmtheranostics.com](https://Radiopharmtheranostics.com).

**ASX ANNOUNCEMENT**  
**5 August 2024**



**Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.**

**For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: rc@radiopharmtheranostics.com

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: matt@nwrcommunications.com.au

**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>  
Twitter – <https://twitter.com/TeamRadiopharm>  
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>  
InvestorHub – <https://investorhub.radiopharmtheranostics.com/>